CardioGenics Holdings Inc (CGNH) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerCardioGenics Holdings Inc (CGNH) trades at $0.0001. CardioGenics Holdings Inc. develops and commercializes diagnostic test products for the in vitro diagnostics testing market. Their QL Care Analyzer and immunoassay tests aim to improve point-of-care diagnostics. Sector: Healthcare.
Price as of · Last analyzed: Mar 16, 2026Analyst Coverage for CGNH: CGNH does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
CardioGenics Holdings Inc (CGNH) Healthcare & Pipeline Overview
CardioGenics Holdings Inc. focuses on point-of-care diagnostic solutions, offering the QL Care Analyzer and a range of immunoassay tests. Targeting the in vitro diagnostics market, the company aims to provide rapid and accurate diagnostic tools for cardiac markers and other applications, primarily across the United States, Canada, and Europe.
What Is the Investment Thesis for CGNH?
CardioGenics Holdings Inc. presents a high-risk, high-reward investment profile due to its focus on the point-of-care diagnostics market. The company's QL Care Analyzer and cardiac marker tests address a critical need for rapid and accurate diagnostics. A key value driver is the potential for widespread adoption of the QL Care Analyzer in hospitals and clinics. Growth catalysts include regulatory approvals in key markets and strategic partnerships for distribution. However, the company faces significant challenges, including limited financial resources, intense competition, and the need for successful commercialization of its products. With a market capitalization of $0.00B and a beta of 20.77, CGNH exhibits substantial volatility. Successful execution of its commercialization strategy is crucial for realizing its potential.
Based on FMP financials and quantitative analysis
CGNH Key Highlights
CardioGenics Holdings Inc. operates in the in vitro diagnostics market, focusing on point-of-care testing.
- The company's QL Care Analyzer is a portable, automated immunoassay analyzer designed for rapid results.
- CardioGenics offers immunoassay tests for cardiac markers, aiding in the diagnosis of heart attacks.
- The company's products target markets in the United States, Canada, and Europe.
- CardioGenics faces strong competition and requires successful commercialization to achieve growth.
Who Are CGNH's Competitors?
CGNH is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| INBS Intelligent Bio Solutions Inc. | $1.66 | 0.00% | $5.51M | — |
| NDRA ENDRA Life Sciences Inc. | $6.06 | +3.06% | $7.70M | 32 5-pillar |
| ADVB Advanced Biomed Inc. Common Stock | $6.73 | -2.60% | $9.30M | 62 5-pillar |
| BNGO Bionano Genomics, Inc. | $1.48 | -5.73% | $17.0M | — |
| BNR Burning Rock Biotech Limited | $16.25 | +1.63% | $17.2M | — |
| MDXH MDxHealth SA | $0.57 | -0.90% | $29.3M | — |
| QUCY QUCY | $1.34 | -0.74% | $30.5M | — |
| STRR Star Equity Holdings, Inc. | $9.76 | -1.11% | $36.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CGNH's Key Strengths?
Proprietary QL Care Analyzer technology
- Focus on point-of-care testing
- Potential for rapid diagnostic results
- Production of paramagnetic beads
What Are CGNH's Weaknesses?
Limited financial resources
- Small number of employees
- Dependence on single product line
- OTC market listing
What Are the Key Risks for CGNH?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Limited financial resources to support commercialization efforts.
- Intense competition from established players in the in vitro diagnostics market.
- Regulatory hurdles and approval processes for new products.
- Dependence on the success of the QL Care Analyzer platform.
- OTC market listing and associated risks.
What Threats Does CGNH Face?
- Intense competition from established players
- Regulatory hurdles and approval processes
- Technological obsolescence
- Economic downturn affecting healthcare spending
What Are CGNH's Competitive Advantages?
- Proprietary QL Care Analyzer technology.
- Focus on point-of-care testing market.
- Development of specific immunoassay tests for cardiac markers.
- Production of paramagnetic beads for immunoassay applications.
What Does CGNH Do?
CardioGenics Holdings Inc., originally founded in 1997 as Jag Media Holdings, transitioned to its current focus on in vitro diagnostics in 2009. The company develops and commercializes diagnostic test products, with a focus on point-of-care (POC) solutions. Its flagship product is the QL Care Analyzer, a portable, stand-alone, and automated immunoassay analyzer. This system utilizes proprietary self-metering cartridges to perform immunoassay tests directly at the point of care, enabling rapid results. CardioGenics also offers a series of immunoassay tests designed to identify cardiac markers in the blood, crucial for the timely diagnosis of heart attacks. Additionally, the company produces paramagnetic beads used as solid surfaces in heterogeneous immunoassay tests by clinical and research laboratories. CardioGenics aims to improve diagnostic accuracy and speed, particularly in critical care settings. Headquartered in Mississauga, Canada, the company targets markets in the United States, Canada, and Europe.
What Products and Services Does CGNH Offer?
- Develop and commercialize diagnostic test products.
- Focus on in vitro diagnostics testing market.
- Offer the QL Care Analyzer, a portable immunoassay analyzer.
- Provide immunoassay tests to identify cardiac markers.
- Produce paramagnetic beads for use in immunoassay tests.
- Target point-of-care testing applications.
How Does CGNH Make Money?
- Sales of QL Care Analyzer systems to hospitals and clinics.
- Sales of immunoassay test cartridges for use with the QL Care Analyzer.
- Sales of paramagnetic beads to clinical and research laboratories.
- Potential revenue from service and maintenance contracts for the QL Care Analyzer.
What Industry Does CGNH Operate In?
CardioGenics Holdings Inc. operates within the in vitro diagnostics market, a segment of the broader healthcare industry experiencing steady growth driven by technological advancements and increasing demand for rapid and accurate diagnostic testing. The point-of-care diagnostics sub-segment is particularly attractive, offering the potential for faster turnaround times and improved patient outcomes. However, the market is highly competitive, with established players like BMGP and HLUN holding significant market share. CardioGenics must differentiate itself through innovative technology, strategic partnerships, and effective commercialization to succeed.
Who Are CGNH's Key Customers?
- Hospitals and clinics requiring point-of-care diagnostic solutions.
- Clinical laboratories performing immunoassay tests.
- Research laboratories using immunoassay techniques.
- Healthcare providers seeking rapid and accurate diagnostic results.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Company Profile
CardioGenics Holdings Inc operates in the Medical - Diagnostics & Research industry within the Healthcare sector. It is headquartered in Mississauga, CA. The company is led by CEO Yahia Abdul Gawad. CGNH has traded publicly since 2004.
Key Financial Metrics
Return on equity for CardioGenics Holdings Inc stands at 141.0%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
CardioGenics Holdings Inc's Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
CGNH Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
CGNH Latest News
-
CardioGenics (OTCMKTS:CGNH) Shares Cross Above Two Hundred Day Moving Average – Should You Sell?
defenseworld.net · Aug 21, 2026
CGNH Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for CGNH.
Price Targets
Wall Street price target analysis for CGNH.
CGNH MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for CGNH; grades run from A+ (80-100) to F (below 30).
Leadership: Yahia Abdul Gawad
CEO
Yahia Abdul Gawad serves as the CEO of CardioGenics Holdings Inc. As CEO, he is responsible for leading the company's strategic direction and overseeing its operations in the development and commercialization of diagnostic test products.
Track Record: Due to limited information, Yahia Abdul Gawad's specific achievements and strategic decisions as CEO of CardioGenics Holdings Inc. cannot be detailed. His tenure involves navigating the company's focus on point-of-care diagnostics and managing a small team of employees.
CGNH OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that CardioGenics Holdings Inc. may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited trading volume and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and liquidity.
- OTC Tier: OTC Other
- Limited financial disclosure
- Low trading volume and liquidity
- Potential for price manipulation
- Higher risk of fraud or mismanagement
- Limited regulatory oversight
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Understand the company's capital structure and ownership.
- Consult with a qualified financial advisor.
- Company has been in operation since 1997.
- Focus on developing and commercializing diagnostic test products.
- QL Care Analyzer and immunoassay tests address a specific market need.
- Headquartered in Mississauga, Canada.
Common Questions About CGNH (Healthcare)
What are the main risks for CGNH?
CardioGenics Holdings Inc. faces several key risks. These include limited financial resources, intense competition in the in vitro diagnostics market, regulatory hurdles for product approvals, and dependence on the success of the QL Care Analyzer platform.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available for CardioGenics Holdings Inc.